loading...| Preferred Name |
Brilacidin |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169816 |
| CAS_Registry |
1224095-98-0 |
| code |
C169816 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 |
| Contributing_Source |
FDA |
| DEFINITION |
A synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins. |
| FDA_UNII_Code |
I1679X069H |
| FULL_SYN |
PMX-30063 Brilacidin BRILACIDIN PMX 30063 PMX30063 |
| label |
Brilacidin |
| NCI_META_CUI |
CL1382168 |
| Preferred_Name |
Brilacidin |
| prefixIRI |
Thesaurus:C169816 |
| prefLabel |
Brilacidin |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.bioontology.org/ontology/MESH/C000611530 | Medical Subject Headings / 医学主题词表 | LOOM |